President Trump hosted a private dinner with Anthropic CEO Dario Amodei at the White House, signaling a possible thaw after months of conflict over the Pentagon's exclusion of Anthropic as a supply-chain risk. The meeting comes shortly after a federal appeals court upheld the Pentagon's decision to restrict Anthropic's AI technology use, citing operational risks. Despite Trump's skepticism about slowing AI development, Amodei advocates for cautious oversight to address AI safety concerns. This meeting may indicate a new phase in dialogue between the government and the AI firm amid ongoing legal and strategic tensions.
The Technology-sector on Pluang saw only 15 of 150 priced US stocks rise while 133 fell, providing market context for the Trump and Anthropic CEO Dario Amodei dinner story. For readers following this, here is Pluang's market snapshot as of Sep 28, 2026 21:51 WIB: Intel Corp (INTC) was down 5.97% at USD 115.66 with a typical hold time of 116 days, Braze Inc (BRZE) fell 5.87% to USD 22.94 with a 60-day hold, and HubSpot Inc (HUBS) dropped 5.49% to USD 202.00 with a 76-day hold time.
Vertex Pharmaceuticals reported a 12% revenue increase to $3.33 billion in Q2, driven by its dominant cystic fibrosis treatments. UBS raised its price target from $585 to $615, reflecting confidence in Vertex's strong financials and growth potential....
Accenture's stock surged 37.6% recently, driven by rising demand for AI services and new AI-focused offerings. The company outpaced industry growth and secured 100 new clients for advanced AI projects in one quarter. An analyst raised the price targe...
SpaceX, trading near $148 per share with a market cap of about $1.95 trillion, is preparing for Starship's first orbital mission and the deployment of its first operational Starlink V3 satellites. This milestone is key for expanding Starlink's global...
Argus Research initiated coverage on 10x Genomics with a Buy rating and a $110 price target, suggesting a 28% upside from its current price of around $85. The stock shows strong momentum, trading well above its 50-day and 200-day moving averages. How...
Morgan Stanley reaffirmed an "Overweight" rating on Cullen/Frost Bankers, Inc., raising its price target to $201, signaling confidence in the bank's prospects. Major institutional investors like State Street Corp and BlackRock have increased or initi...
